The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer.

ABSTRACT:

Background

Breast cancer, one of the most common forms of cancer, is associated with the highest cancer-related mortality among women worldwide. In comparison to other types of breast cancer, patients diagnosed with the triple-negative breast cancer (TNBC) subtype have the worst outcome because current therapies do not produce long-lasting responses. Hence, innovative therapies that produce persisting responses are a critical need. We previously discovered that hyperactivating purinergic receptors (P2RXs) by increasing extracellular adenosine triphosphate (eATP) concentrations enhances TNBC cell lines' response to chemotherapy. Heparan sulfate inhibits multiple extracellular ATPases, so it is a molecule of interest in this regard. In turn, heparanase degrades polysulfated polysacch

SUBMITTER: Manouchehri JM 

PROVIDER: S-EPMC11539583 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature